- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Government Promotes Use of Long-Acting Contraceptives
What we're reading, June 16, 2016: the federal government is encouraging state Medicaid programs to promote long-acting contraceptives; Congress introduces a bill the prevent drug makers from thwarting generic competition; and new recommendation that people can choose the type of colon cancer screening they receive.
The federal government is encouraging state Medicaid programs to increase the number of enrollees using long-acting contraceptives. According to Kaiser Health News, long-acting contraceptives are advantageous because they are cost-effective, highly effective, require little maintenance, and have high patient satisfaction. The government is promoting use of these contraceptives because the United States has one of the highest rates of unintended pregnancies among developed nations, and states and the federal government spent a combined $21 billion on unplanned pregnancies.
Congress has again introduced a bill to prevent drug makers from thwarting generic competition. The bipartisan legislation would target companies that make it difficult to for generic companies to obtain samples of brand-name drugs, according to STAT. The bill would make it easier for generic companies to go to court over drug makers that refuse to make samples available. However, 2 previous legislative efforts have failed.
The US Preventive Services Task Force (USPSTF) is advising that adults can choose the type of colon cancer screening they feel most comfortable with. In addition to the recommended screening tests, USPSTF is now saying people can be screening using CT colonography, reported Reuters. The recommendation is directed at people ages 50 to 75 years.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
